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ABSTRACT
The rationale for B-cell depletion therapy with rituximab in primary Sjögren’s syndrome (pSS) 
relies upon the well-established role of B-cell hyperactivity in immunopathogenesis. In line 
with this notion, several biomarkers of B-cell activity are significantly affected by treatment, 
both in the target organs and periphery. In contrast to most biological outcomes, clinical 
outcomes are not consistent between studies. Although two large RCTs did not meet their 
primary endpoint, several beneficial clinical effects of treatment have been shown. As 
discussed in this review, differences in study design and patient characteristics could explain 
the variation in results. Interestingly, a newly developed composite endpoint of subjective 
and objective outcomes did show a significant effect of rituximab in one of the large RCTs. 
Response predictors need to be identified to define more targeted inclusion criteria and 
achieve precision medicine. The positive effects seen on biological and clinical parameters 
warrant future studies to investigate this promising treatment modality. 
167
INTRODUCTION
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease with a heterogeneous 
clinical presentation. Predominant symptoms of pSS are dryness of mouth and eyes, but many 
patients also suffer from extraglandular symptoms, including chronic fatigue, arthralgia and 
involvement of lungs, skin, kidneys and the nervous system. Dysfunction of exocrine glands 
is accompanied by periductal mononuclear infiltration of these glands, mainly by CD4+ T cells 
and B cells. Involvement of B cells in pSS pathogenesis is further illustrated by the presence 
of autoantibodies directed against SS-A/Ro and/or SS-B /La, elevated levels of rheumatoid 
factor (RF), hypergammaglobulinemia, elevated levels of Bruton’s tyrosine kinase in B cells 
and a significantly increased risk of Non-Hodgkin B cell lymphoma, predominantly mucosa-
associated lymphoid tissue (MALT) lymphoma1,2. 
The prominent role of B cell hyperactivity in pSS pathogenesis provides a rationale for 
the use of rituximab, a humanized anti-CD20 monoclonal antibody, to treat this disease. 
Binding of rituximab to CD20-expressing B cells results in a significant depletion of these 
cells via antibody-dependent cellular cytotoxicity, complement mediated cytotoxicity and 
apoptosis3. Plasma cells are not directly depleted by rituximab, because expression of CD20 is 
downregulated when B cells differentiate towards plasma cells, but formation of new plasma 
cells may be impaired by B cell depletion therapy. Although initial studies in pSS showed 
improvement of both subjective and objective parameters4–7, two large placebo-controlled 
trials8,9 did not confirm all promising results of the earlier studies. Possible explanations for this 
discrepancy are heterogeneity in patient characteristics, primary end points and background 
medication use, which will all be discussed in this review. Consensus on the efficacy of 
rituximab in pSS is currently lacking, but treatment results in several clinical, biological and 
histological improvements. Furthermore, treatment studies with rituximab in pSS provided 
insights in the pathogenic mechanisms of the disease and post-hoc analyses of biological 
parameters have identified possible biomarkers that can predict response. These biomarkers 
may characterize subgroups of pSS patients that benefit from rituximab before start of 
treatment. Future studies with B cell-targeting therapy can contribute to identification of new 
predictors of response, as well as development of sensitive and accurate outcome measures 
for future clinical trials in pSS.  
EFFECTS OF RITUXIMAB ON B CELL HYPERACTIVITY
Systemic markers of B cell hyperactivity
Several biomarkers of B cell activation, including gammaglobulins, autoantibodies (RF, anti-
SS-A/Ro, anti-SS-B/La), β2-microglobulin, free light chains and B cell activating factor (BAFF/
Blys) have been studied in the context of rituximab treatment in pSS (figure 1). A small but 
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significant gradual decrease in total serum IgG after 24 weeks of treatment is seen in larger 
studies (Table 1)4,8,10. At the same time, a decrease in RF levels (up to 50%) is observed (Table 
1)4,6,10–12. Interestingly, Dass et al. found that a non-responder had less reduction in RF after 
treatment compared with responders6. Following B cell repopulation, RF levels rise again 
and this rise can predict relapse of clinical symptoms5,12. Similar to findings in rheumatoid 
arthritis (RA), combined presence of RF and disease–specific autoantibodies (anti-SS-A/Ro, 
anti-SS-B/La) may result in higher disease activity in pSS as well13. The mechanism behind this 
synergistic effect in unknown, but crosslinking and/or stabilization of immune complexes, 
consisting of autoantigens and autoantibodies, by RF is likely involved. In combination with 
the finding that higher RF levels seem to increase the risk of lymphoma14, these data suggest 
that lowering RF levels by rituximab treatment is of clinical importance, as it may protect 
against disease progression and/or lymphoma development in pSS.
Figure 1. Effects of rituximab treatment on immunopathogenesis of pSS. 
Cytokine production by B cells and (T cell-dependent) formation of plasmablasts and short-lived plasma cells are impaired by B 
cell depletion therapy with rituximab. B cell hyperactivity is reduced, as reflected by lowering of serum IgG, anti-SSA, free light 
chains and rheumatoid factor. Numbers of circulating Tfh cells and serum levels of IL-21 are also decreased. In salivary gland 
tissue, formation of ectopic lymphoid tissue and germinal centers is impaired. FLCs: free light chains; RF: rheumatoid factor. 
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Several studies assessed the effect of rituximab on anti-SS-A/Ro or anti-SSB/La serum levels in 
pSS patients. While three studies did not find significant changes in anti-SS-A/Ro or anti-SS-B/
La autoantibodies after treatment7,15,16, we found a significant reduction of ±25% in anti-SS-A/
Ro and anti-SS-B/La titers at 16 weeks after treatment (Table 1)17. The discrepancy between 
studies may be explained by differences in study population size, baseline systemic disease 
activity, time point of measurements, or differences in reliability of the immunoassay, but 
methods for anti-SS-A/Ro and anti-SS-B/La measurement were not specified in most studies. 
The observed reduction in autoantibodies is likely a result of decreased generation of short-
lived plasma cells, due to depletion of CD20+ precursor cells, and/or direct depletion of 
CD20-expressing (short-lived) plasma cells. There is evidence that anti-SSA/Ro60 antibody 
production depends –at least partially- on clonal turnover of short-lived plasma cells and this 
may also be true for other autoantibodies18. B cell depletion therapy can therefore directly 
affect autoantibody production in pSS patients.








Patients on concomitant 
immunomodulatory drugs (n (%))
DMARDS Steroids
Pijpe et al.11 15 = ↓a NA ↓ 3 (20) 3 (20)
Devauchelle-Pensec et al.15 16 = = ↓b ↓ 0 (0) 0 (0)
Dass et al.6 8 ↓b ↓ NA NA NA NA
Meijer et al.69 5 NA ↓ NA NA 0 (0) 0 (0)
Meijer et al.4 20 ↓ ↓ NA ↓ 0 (0) 0 (0)
Gottenberg et al.50 78 NA NA NA NA 29 (37) 17 (22)
Carubbi et al.7 19 = = = ↓ 0 (0) 19 (100)
St. Clair et al.16 12 NA ↓b = NA 8 (67) 3 (25)
Devauchelle-Pensec et al.8 63 ↓ NA NA ↓ 10 (19) 17 (32)
Meiners et al.5 28 ↓ ↓ ↓ NA 0 (0) 0 (0)
Bowman et al.9 67 NA NA NA NA 39 (58) 7 (10)
Arrows indicate a decrease. aOnly in patients with MALT/pSS. bNot statistically significant. NA: not available.
In addition to gammaglobulin and autoantibody levels, other indicators of B cell hyperactivity 
in pSS are also affected by rituximab treatment. β2-microglobulin levels show a ‘delayed’ 
drop at 16 weeks after treatment8,12, which was not seen at 6 or 12 weeks after rituximab 
treatment8,11. Serum immunoglobulin free light chains (FLCs) are also affected by rituximab 
and decrease significantly from week 5 up to week 48 after treatment (unpublished data), 
in line with findings in RA19. Both β2-microglobulin and FLC baseline levels in serum of pSS 
patients are positively correlated to ESSDAI scores20, suggesting that there is a link between 
the degree of B cell activation and systemic disease activity. Serum levels of several B cell-
associated cytokines, including IL-6, GM-CSF, TNF-α and IL-10, are also lowered by rituximab21. 
Whether this decrease is the consequence of removal of cytokine-producing B cells, or is 
caused by indirect effects of B cell depletion on cytokine production by other cells is not 
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yet known. In contrast to the B cell-associated cytokines mentioned above, serum BAFF 
levels increase after B cell depletion therapy, likely due to unavailability of BAFF receptors as 
a consequence of the absence of B cells22. This rise in BAFF levels may be unfavorable for the 
patient due to enhanced survival of autoreactive B cell clones and skewing of newly formed 
B cells towards an autoreactive phenotype23,24. Therefore, the efficacy of therapy combining B 
cell depletion and BAFF-blockade is currently under investigation (NCT02631538). 
In summary, most biomarkers of B cell activation in the circulation are decreased by B cell 
depletion therapy (figure 1). Lowering of B cell activation likely contributes to amelioration 
of systemic disease activity in pSS patients, due to lower levels of autoantibodies and pro-
inflammatory cytokines. 
Histological markers of B cell hyperactivity
B cells infiltrate the glandular tissue of pSS patients, accumulate around the ductal epithelium 
and, together with stromal cells and follicular dendritic cells, orchestrate formation of ectopic 
lymphoid tissue. Importantly, rituximab clearly reduces the total number and proportion of 
infiltrating B cells in both minor and major salivary glands (Table 1)7,25,26. In addition, as shown 
in minor salivary gland tissue, rituximab decreases mRNA expression of lymphotoxin (LT)-α 
and –β, important for lymphoid organogenesis [7]. The reduction of lymphotoxin is likely 
a direct result of lower B cell numbers in the glands, as the heterodimer LTα1β2 is mainly 
produced by B cells27. Lowering of B cell numbers is further accompanied by a decline in 
germinal centers located within ectopic lymphoid tissue of the glands28. This decline is likely 
caused both by direct depletion of B cells, as well as reduced presence of Tfh cells (figure 1)17. 
B cells often infiltrate the ductal epithelium of the salivary glands, resulting in the 
development of lymphoepithelial lesions. Most of these intra-epithelial B cells belong to 
a unique subset of cells expressing FcRL4 and these cells possibly function as precursor 
cells for MALT lymphoma29. We have found that intra-epithelial FcRL4+ B cells are almost 
completely depleted by rituximab29. Furthermore, rituximab treatment reduces the severity 
of lymphoepithelial lesions, and concomitantly leads to restoration of the epithelium25. It 
would be of value to study whether rituximab-treated patients develop MALT-lymphoma 
less frequently than untreated patients. 
As expected, plasma cells can persist in parotid glands of pSS patients despite B cell depletion 
therapy, since they lack expression of CD2030. However, it is not known if absolute numbers of 
plasma cells in salivary glands are affected by rituximab and whether this is associated with 
response to treatment. In synovial tissue of RA patients, a larger decrease in synovial plasma 
cells was observed in responders versus non-responders31.  Therefore, it is of interest to study 
local plasma cell numbers in pSS patients after rituximab.
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EFFECTS OF RITUXIMAB ON THE CD4+ T CELL COMPARTMENT
Depletion of B cells abrogates antigen presentation and cytokine production by these cells 
and rituximab treatment may therefore affect other cell types, in particular CD4+ T cells (figure 
1)32. Patients with pSS have elevated proportions of circulating T follicular helper (cTfh) cells, 
defined as CXCR5+PD-1+CD45RA-CD4+ cells, compared with healthy controls17,33,34. The B cell 
hyperactivity that is present in pSS patients may favor differentiation of Tfh cells through 
secretion of IL-6 by activated B cells in conjunction with high expression of co-stimulatory 
molecules (e.g., CD40, ICOS-L)35,36. Tfh cells subsequently activate B cells and promote 
germinal center formation and plasma cell formation36, providing a positive-feedback loop. 
We have recently shown that cTfh cells, and to a smaller extent also Th17 cells, are reduced by 
rituximab17. The decrease in cTfh cells correlates with lowering of ESSDAI scores, emphasizing 
their potential role in the disease process. Reduced frequencies and numbers of cTfh cells and 
Th17 cells during B cell depletion are accompanied by decreased serum levels of IL-21 and 
IL-17. Th17 cells in minor salivary glands are also reduced by rituximab, but the effect on local 
Tfh cells is not known yet37,38. Depletion of the small fraction of Th17 cells that co-expresses 
CD20 may contribute to the decrease in Th17 cells39. Thus, taking all the biological effects of 
rituximab on (T cell-mediated) B cell hyperactivity together, these findings may –at least in 
part- underlie beneficial clinical outcomes of rituximab in pSS patients. 
CLINICAL EFFICACY OF RITUXIMAB IN PRIMARY SJÖGREN’S 
SYNDROME
Several open-label and randomized controlled trials have been performed to date, including 
two larger RCTs: the TEARS and TRACTISS trials8,9. In tables 2 and 3, population characteristics 
and clinical outcomes of all prospective clinical trials reported in literature are summarized. 
Despite the generally acknowledged beneficial effects of rituximab treatment on biological 
parameters, clinical outcomes vary between studies. 
Effects on exocrine gland function and sicca symptoms
Objective measures of salivary gland function include unstimulated whole salivary flow 
(UWS) and stimulated whole salivary flow (SWS). UWS depends mainly on submandibular 
gland function, while SWS depends on both submandibular and parotid gland function. The 
ratio of parotid and submandibular saliva in SWS depends on the method of stimulation 
(mechanical vs. citric acid stimulation). UWS and SWS are both outcomes of interest. However, 
it is important to realize that patients show substantial intra-individual variability in salivary 
flow, resulting in a large standard deviation40,41. Therefore, adequate sample sizes are needed 
to show the effect of treatment on salivary gland function.  
9
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Meijer et al. and Carubbi et al. showed significant improvement in UWS after rituximab 
treatment4,7. In other trials, including the TEARS trial, no effect on UWS was observed6,8,11,15. 
Although the mean baseline UWS in the TEARS trial was comparable to the study of Meijer et 
al., the standard deviation was twice as high, which may influence the power of their analysis. 
St. Clair et al. did not find an effect on UWS, but included patients with low to absent UWS 
at baseline, who therefore may have had irreversible destruction of glandular parenchyma16. 
Recently, Bowman et al. showed that UWS of patients in the rituximab group of the TRACTISS 
trial remained stable, while the placebo group deteriorated9. 
Only few studies measured the effect of rituximab on SWS. Pijpe et al. showed that rituximab 
improved stimulated submandibular/sublingual salivary flow only in patients with residual 
salivary gland function at baseline (SWS >0.10 ml/minute)11. Similarly, in the RCT by Meijer et al. 
only patients with a SWS ≥0.15 ml/minute were included, and SWS was significantly increased 
in the rituximab group, while it deteriorated in the placebo group4. Unfortunately, recent RCTs 
did not measure SWS. 
Currently, there is a growing interest in salivary gland ultrasound for assessment of the salivary 
gland structure, as it is non-invasive and inexpensive. The first study using ultrasound showed 
a reduction in size of the parotid and submandibular glands after rituximab treatment42. In a 
sub-analysis of the TEARS study, parotid parenchyma echostructure improved in 50% of the 
rituximab-treated patients versus 7% in the placebo group, visualizing histological changes 
induced by rituximab (referentie?)43. 
In summary, there seems to be a beneficial effect of rituximab on salivary gland function and 
structure, but the effect size is small and varies between studies. Echostructure of the gland 
seems to improve by rituximab, in line with the histological effects. The observed decrease in 
glandular B cells and (partial) restoration of the ductal epithelium in patients after treatment 
may contribute to the increase in salivary flow, but additional factors that affect salivary flow 
in pSS patients need to be identified. Lastly, it should be considered that severe destruction 
of parenchyma may not be reversed by immunomodulatory treatment, but such treatment 
could halt further damage in patients with residual gland function.
Tear gland function was assessed by Schirmer’s test in most studies. Only one out of seven 
studies showed significant improvement in Schirmer’s test after treatment (table 3)7. The TEARS 
study showed a stable Schirmer’s test result in the rituximab group, whereas the placebo group 
tended to deteriorate8. Of note, Schirmer’s test may not be suitable to detect small changes 
over time, as it shows low to moderate reliability44. Measurement of the epithelial integrity of 
the ocular conjunctiva by rose Bengal or lissamin green, and cornea by fluorescein staining is 
more reliable to evaluate keratoconjunctivitis sicca45. Interestingly, studies using these ocular 
surface staining methods did show improvement after treatment4,11. This improvement may 
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be caused by effects of rituximab on tear gland morphology and function, composition of 
tear fluid, as well as effects on the inflammatory micro-environment of the ocular surface. For 
example, B cell-derived IL-6 levels in tears correlate with the severity of ocular surface disease, 
reflected by a higher extent of ocular pain, irritation and staining46. More knowledge about 
the effect of rituximab on lacrimal gland inflammation would be valuable, and ocular surface 
staining should be evaluated in all clinical studies, instead of using Schirmer’s test only. 
Besides objective measures of dryness, patient-reported outcomes (PROs) with visual analogue 
scales (VAS) were used in most studies to assess subjective symptoms. Positive results on total 
dryness scores or subscores for oral and ocular dryness were seen in most studies (table 
3). Although no decrease in dryness VAS was seen in de TRACTISS study, improvement was 
seen in the TEARS study8,9. VAS dryness scores improved significantly among patients in the 
rituximab group, although less than 30 mm, which was set as minimum to achieve the primary 
end-point. Furthermore, in a post-hoc analysis, the SS Responder Index (SSRI) was developed, 
which includes VAS scores for fatigue, oral dryness and ocular dryness, as well as UWS and 
ESR. Using this composite endpoint, the proportion of patients with a 30% improvement was 
significantly higher in the rituximab group, compared to the placebo group47. 
Altogether, both subjective symptoms and objective measures of dryness seem to improve or 
at least stabilize during rituximab treatment in most studies. These findings are in accordance 
with histological improvements observed in the salivary glands. A lack of robust objective 
tests and the poor correlation between objective tests and symptoms in pSS may underlie 
the reported variation in study results48. 
Effects on extraglandular manifestations
Fatigue has a major impact on quality of life in pSS patients and is therefore an important target 
for treatment. However, fatigue is a complex and poorly understood feature of the disease and 
can only be measured subjectively49. Most studies measured fatigue by VAS, but more detailed 
instruments such as the multi-dimensional fatigue inventory (MFI) and the Profile of Fatigue 
and Discomfort (PROFAD) questionnaire were also used. Importantly, most studies show that 
fatigue is reduced in pSS patients. All studies, except for the TRACTISS study and a small group 
of patients with advanced disease and MALT lymphoma, showed a positive effect of treatment 
on fatigue (table 3). The largest decrease in fatigue is often seen at early time points (week 4 
in Meijer et al. and week 6 in the TEARS study). This may explain why no effect was seen on 
fatigue in the TRACTISS study, as the first visit in this study was scheduled in week 16. Results 
at early time points may have been biased by initial prednisone treatment to prevent infusion 
reactions. However, fatigue also improved in the open-label study by Devauchelle-Pensec et 
al. where no initial prednisone treatment was given15. In summary, although the effect size is 
small, most studies did show improvements in fatigue. In contrast, symptoms of arthralgia and 
tendomyalgia do not seem to be ameliorated during rituximab treatment (table 3). 
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Rituximab is often used off-label to treat severe systemic manifestations of pSS. The effect of 
rituximab on systemic disease activity was assessed by ESSDAI in several studies, including 
a prospective registry study of off-label treatment with rituximab (table 3). Substantial 
heterogeneity exists within and between study populations regarding systemic disease 
activity (table 2). A significant decrease in ESSDAI score following treatment was seen in 
the RCT of Meijer et al, as reported by Moerman et al., as well as two open label trials and 
the registry study4,7,8,50,51. Improvement was predominantly seen in the glandular, articular, 
hematological and biological domains5, possibly because these ESSDAI domains are more 
likely to change52. The efficacy of rituximab on articular involvement was also confirmed using 
the 28-joint disease activity score (DAS-28)53. Results from the registry study and extrapolation 
of efficacy data from other autoimmune conditions further support the use of rituximab in 
pSS patients with vasculitis and pulmonary involvement50,54. Therefore, these specified clinical 
settings for rituximab treatment were recently included in the clinical practice guidelines of 
the Sjögren’s Syndrome Foundation54. In contrast with earlier findings, no significant effect 
on ESSDAI score was seen in the TEARS and TRACTISS trials8,9. Whereas a lack of effect in the 
TRACTISS study can be explained by relatively low baseline ESSDAI scores (mean 5.3±4.7 for 
the rituximab group), the mean baseline score in the TEARS study was 10±7. Of note, in the 
TEARS study, the ESSDAI was determined retrospectively, which may influence the accuracy 
and reliability. Furthermore, in the TEARS study, the prevalence of baseline involvement in the 
domains that show the highest sensitivity to change, e.g. glandular, constitutional, articular, 
hematological and biological domains, was 29%, 25%, 48%, 38% and 57%, respectively8. These 
percentages are relatively low in comparison to the study by Moerman et al.51, in which these 
domains were active in 70%, 5%, 80%, 55% and 85% of patients, respectively (unpublished 
data). Meiners et al. and Carubbi et al. also reported a higher rate of involvement of most of 
these domains at baseline5,7. In conclusion, four prospective studies have shown beneficial 
effects of rituximab on systemic involvement5,7,50,51. The lack of effect in recent trials may 
be explained by low systemic involvement at baseline or heterogeneity in clinical systemic 
involvement. 
Effects on quality of life
Several studies investigated the effect of rituximab treatment on quality-of-life using the 36-
Item Short Form Health Survey (SF-36). Effects of rituximab treatment were seen in several 
studies in different domains of the SF-36, but with a large variability between studies (table 
3). Interestingly, vitality often improved by treatment. However, the TEARS and TRACTISS trials 
did not observe a significant effect of rituximab treatment on SF-36 scores, compared with 
placebo. This is consistent with findings that subjective symptoms improved only slightly 
(TEARS) or not at all (TRACTISS) in the rituximab group, as subjective symptoms are strong 
predictors of health-related quality-of-life in pSS patients55. 
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PREDICTORS OF RESPONSE TO RITUXIMAB
As described in the previous section, the efficacy of rituximab varies substantially between 
studies. Therefore, it is important to detect possible predictors which enable selection of 
patients that are likely to respond to rituximab treatment. Several predictors of good clinical 
response to rituximab have, for example, already been identified in RA and SLE. In RA, these 
factors are RF or anti-CCP positivity, elevated serum IgG, low IFN activity, lower serum levels 
of BAFF and lower numbers of circulating plasmablasts56. Furthermore, the degree of B 
cell depletion was positively associated with clinical response in both RA and SLE57,58. SLE 
patients with a low-affinity FcγRIIIa genotype have less effective B cell depletion, as antibody-
dependent cellular cytotoxicity, mediated by FcγRIIIa-positive effector cells (mostly NK 
cells), is impaired59. This genotype results in lower binding affinity of FcγRIIIa to anti-CD20 
antibodies that are bound to the target B cells. Whether this FcγRIIIa genotype is also present 
in a subgroup of pSS patients is not known.
In pSS, some predictors of response to rituximab were evaluated. Baseline expression of B cell-
related transcripts and presence of the IFN signature in blood or minor salivary glands were 
not associated with clinical response to rituximab in pSS16,60. Devauchelle-Pensec et al. did 
identify some candidate transcripts, but these need further validation60. Concerning response 
biomarkers in serum, lower serum BAFF levels at baseline were associated with clinical response 
to rituximab in pSS patients, as defined by a ≥30% improvement in at least two items of the SSRI26. 
As mentioned earlier, high BAFF levels may enhance the survival (and prevent the depletion) 
of autoreactive B-cell clones, residing in glandular tissue and/or bone marrow. Besides lower 
BAFF levels, responders to rituximab – based on the SSRI- seemed to have lower baseline B cell 
activity, as reflected by a significantly lower B cell proportion within the glandular infiltrate in 
the labial salivary glands and lower levels of serum anti-SSA and FLCs26. Responders also had a 
lower focus score (median 0.3) and a lower salivary gland ultrasonography grade at baseline, 
compared with non-responders26,43. Based on these characteristics, responders may have less 
irreversible gland destruction and respond to rituximab based on SSRI improvement, since VAS 
dryness scores and UWS are two of the five measures that constitute the SSRI. 
Using a different definition of clinical response, i.e., a decrease of ≥3 in the ESSDAI, we have 
shown that both baseline absolute numbers of B cells and the B cell proportion in parotid 
gland tissue are higher in responders versus non-responders25,61. Explanations for the 
apparent discrepancy between the study of Cornec et al. and our study have been extensively 
discussed elsewhere61,62. Our findings that high absolute numbers and proportions of B cells 
in the parotid gland are associated with ESSDAI response suggest that the number of B cells 
in the target tissue influences systemic disease activity. Likewise, the B cell proportion in the 
labial gland positively correlates with markers of systemic B-cell hyperactivation63. 
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Together, these data indicate that rituximab may be effective in either patients with low 
salivary gland inflammation, to prevent further glandular damage, or in patients with high 
numbers of infiltrated B cells and high systemic disease activity, to ameliorate activity in 
specified ESSDAI domains61. 
WHY DOES THE EFFICACY OF RITUXIMAB VARY BETWEEN STUDIES?
As discussed in the previous paragraphs, results from several trials of rituximab treatment for 
pSS vary. First, the use of different inclusion criteria, leading to differences in baseline patient 
characteristics, may explain part of this variation. Since rituximab has shown to -at least- halt 
further deterioration of glandular function, compared with placebo, treating patients early in 
the disease process may prevent progression of irreversible damage to the glands. Therefore, 
the majority of the studies incorporated a limited disease duration (range 2-10 years) as an 
inclusion criterion, but still there are large differences in disease duration between the study 
populations. Besides disease duration, patients characteristics such as mean age, IgG levels, 
and salivary flow also differ among study populations. For example, mean age is ±10 years 
lower in the studies by Meijer et al. and Carubbi et al., and mean IgG is higher in the study by 
Meijer et al., compared to other studies4,7. In addition, there may be other unspecified patient 
characteristics that influence treatment response. For example, ±80% of pSS patients show 
poor correlation between reported ocular dryness symptoms and objective parameters of 
gland function, caused by either under- or over-reporting of symptoms48. The number of 
patients under- or over-reporting their symptoms included in a trial may influence the results. 
Moreover, a study by Lendrem et al. identified four phenotypic clusters using hierarchical 
clustering of patient-reported pain, fatigue, dryness, anxiety and depression, and found 
significant differences in IgG, lymphocytes, ESR, ESSDAI score, and UWS between groups64. 
Presumably, these groups may show different responses to rituximab treatment. 
Another possible cause of discrepancies between studies is the use of (stable) background 
medication. In the TEARS and TRACTISS studies, respectively 51% and 68% of the patients 
used either concomitant DMARDs (mostly hydroxychloroquine) or prednisone (table 1). 
Hydroxychloroquine and prednisone both have significant effects on the immune system, 
making it more difficult to show additional effects of rituximab. 
Differences in statistical analysis may also contribute to the variation in reported outcomes. 
Several studies use paired tests between baseline and multiple time points, whereas specific 
methods for longitudinal data analysis are available that increase statistical power and reduce 
multiple testing problems. Generalized estimating equations (GEE), for example, take into 
account the fact that repeated measurements within one individual are correlated and GEE is 
therefore a more powerful tool to detect even small changes over time.
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Finally, discrepancy between studies is also caused by the use of different outcome measures. 
No consensus has been reached about the ideal combination of outcome measures to 
measure treatment efficacy in pSS. The two large RCTs (TEARS and TRACTISS) have used 
change in subjective symptoms (VAS scores) as primary outcome measures8,9. Subjective 
symptoms such as fatigue and sicca symptoms account for a great loss in quality of life and 
are indeed an important target for treatment. However, the sensitivity to change of these 
outcome measurements has not been validated, and the response goals were set quite high 
(30mm change in 2 out of 4 VAS scores in TEARS, 30% change of either oral dryness or fatigue 
VAS score in TRACTISS). These goals may have been too high, considering that the ESSPRI has 
a minimal clinically important improvement of 1 point (out of 10) or 15% change. Sensitivity 
to change may be improved by the use of more precise PROs, such as the Patient-Reported 
Outcomes Measurement Information System (PROMIS), developed by the National Institutes 
of Health65. Importantly, there is a poor correlation between subjective and objective 
measures of dryness in pSS48. Until we are able to understand these discrepancies, subjective 
and objective measurements of dryness should be equally weighted in the evaluation of 
treatment efficacy. In line with this notion, Cornec et al. proposed a new data-driven composite 
outcome which combines objective manifestations and subjective symptoms, the SSRI47. This 
outcome was established by combination of five outcome measures that were improved by 
rituximab in the TEARS trial. Although the combination of subjective and objective measures 
as primary outcome is of interest, the SSRI needs to be refined and validated in other clinical 
studies. 
For objective measurement of systemic activity in pSS, introduction of the ESSDAI in 2010 
has been a big step forward66. Before that, trials did not have a validated tool to assess the 
effect of rituximab treatment on systemic disease activity. In later trials, most improvement 
was seen in domains with the highest activity at baseline5 and a minimal clinically important 
improvement in ESSDAI of at least three points was determined67. Recent trials in pSS have 
therefore focused on including patients with moderate-to-high ESSDAI scores (≥5), to be able 
to show an effect on extraglandular manifestations. 
Although the ESSDAI has been validated and is now being used in most clinical trials, there 
are also disadvantages regarding the use of ESSDAI as outcome measure. It is now recognized 
that not all ESSDAI domains show sensitivity to change52. Consequently, even in populations 
with comparable mean ESSDAI scores, differences in which ESSDAI domains are active 
at baseline may greatly influence response to rituximab. To prove efficacy of rituximab on 
systemic disease activity, future trials should therefore include patients with moderate-to-high 
ESSDAI scores and activity in at least one of the domains that is likely to change (biological, 
articular, hematological, pulmonary, and glandular domains). Prospective use of specific 
indices for separate domains, such as the DAS-28 for articular involvement, may provide more 
detailed information on efficacy. For example, it is difficult to detect moderate changes in 
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patients with high baseline IgG levels, using the biological domain of the ESSDAI. Additionally, 
researchers should be aware of the complexity of ESSDAI, which needs to be completed 
by rheumatologists who are trained and experienced in doing so. In a multi-center setting, 
this may not always be the case. A more detailed user guide has been published, which 
may increase the accuracy of the ESSDAI68. Considering that rituximab shows effect in several 
domains of the ESSDAI, patients with high ESSDAI scores may be the target population that 
we should aim for. Future trials should explore composite endpoints, which include selected 
domains of the ESSDAI score, besides subjective symptoms and gland function. 
CONCLUSIONS AND FUTURE DIRECTIONS
Rituximab shows beneficial effects on B cell activity, glandular morphology, dryness, fatigue 
and several extraglandular manifestations in pSS patients. Although two large RCTs did not 
meet their primary endpoint, the sensitivity to change of their subjective endpoints may 
be limited. Future trials should evaluate clinical and biological predictors of response and 
explore the use of composite endpoints such as the SSRI. We believe that there is still room for 
new trials with anti-CD20 biologicals, as well as with other B cell-targeting therapies, such as 
anti-CD22 or anti-BAFF/Blys antibodies for the treatment of pSS, in well-defined populations 
with moderate to high ESSDAI scores. At the same time, data on long-term (>1 year) efficacy 
of rituximab and preventive effects on development of extraglandular manifestations and/
or lymphoma are needed and may support the use of rituximab in pSS. The effectiveness of 
pSS has not been proven for all pSS patients, but in our opinion, rituximab is of great value 
to treat patients with systemic manifestations of pSS and we should not throw the baby out 
with the bath water.
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